...
首页> 外文期刊>Radiology >Investigational Vertebroplasty Safety and Efficacy Trial (INVEST): Patient-reported outcomes through 1 year
【24h】

Investigational Vertebroplasty Safety and Efficacy Trial (INVEST): Patient-reported outcomes through 1 year

机译:椎体成形术安全性和有效性试验(INVEST):患者报告的1年结局

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To evaluate 1-year outcomes of the Investigational Vertebroplasty Safety and Efficacy Trial (INVEST), a blinded, randomized, controlled trial to investigate the effectiveness of percutaneous vertebroplasty in the treatment of osteoporotic vertebral compression fractures. Materials and Methods: Patients were enrolled at 11 sites in the United States, the United Kingdom, and Australia by using an institutional review board-approved protocol and HIPAA compliance, and all patients provided written informed consent. Patients were randomized to undergo vertebroplasty or a control procedure. After 1 month, patients were allowed to cross over and undergo the alternate procedure. Coprimary outcomes were patient-reported function, measured with the modified Roland-Morris Disability Questionnaire (RDQ), and pain (on a scale of one to 10) at 1 year. Intention-to-treat (ITT) and as-treated (AT) analyses were used to compare outcomes. Results: One hundred thirty-one participants (68 in the vertebroplasty group and 63 in the control group) were included in the analyses. Patients in both groups showed improvements in pain and function at 1 year. In ITT analyses, patients randomized to vertebroplasty did not differ from control subjects in terms of RDQ results (difference, 1.37 points; 95% confidence interval [CI]: -0.88, 3.62; P = .231) but reported lower levels of pain (difference, 1.02 points; 95% CI: 0.04, 2.01; P = .042). Eleven of 68 patients who underwent vertebroplasty (16%) and 38 of 63 control subjects (60%) crossed over and elected to undergo the alternate procedure (P < .001). In AT analyses, patients treated with vertebroplasty did not differ from control subjects in terms of RDQ results (difference, 0.66 points; 95% CI: 21.98, 3.30; P = .625) or pain (difference, 0.85 points; 95% CI: 20.35, 2.05; P = .166). Conclusion: Vertebroplasty may provide a modest reduction in pain at 1 year compared with a control procedure; however, no difference in functional disability was observed.
机译:目的:评估一项椎体成形术安全性和有效性试验(INVEST)的1年结果,这是一项盲法,随机对照试验,旨在研究经皮椎体成形术在治疗骨质疏松性椎体压缩性骨折中的有效性。资料和方法:通过机构审查委员会批准的方案和HIPAA依从性,在美国,英国和澳大利亚的11个地点招募了患者,所有患者均提供了书面知情同意书。患者被随机接受椎体成形术或对照程序。 1个月后,允许患者越过并接受替代程序。共同的主要结果是患者报告的功能(用改良的Roland-Morris残疾问卷(RDQ)测量)和1年时的疼痛(范围为1到10)。意图治疗(ITT)和治疗后(AT)分析用于比较结果。结果:131位参与者(椎体成形术组68位,对照组63位)被纳入分析。两组患者在1年时疼痛和功能均得到改善。在ITT分析中,随机分组进行椎体成形术的患者在RDQ结果方面与对照组无差异(差异1.37分; 95%置信区间[CI]:-0.88,3.62; P = .231),但疼痛水平较低(差,1.02点; 95%CI:0.04,2.01; P = .042)。 68例接受椎体成形术的患者中有11例(16%)和63例对照对象中的38例(60%)进行了交叉手术,并选择接受替代手术(P <.001)。在AT分析中,接受椎体成形术治疗的患者与RDQ结果(差异为0.66点; 95%CI:21.98,3.30; P = .625)或疼痛(差异为0.85点; 95%CI: 20.35,2.05; P = 0.166)。结论:与对照组相比,椎体成形术可在1年时减轻疼痛。但是,没有观察到功能障碍的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号